Related references
Note: Only part of the references are listed.Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis
Maria Theresa Arias et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
The Pharmacokinetics of Biologics: A Primer
Diane R. Mould
DIGESTIVE DISEASES (2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays
Thomas Van Stappen et al.
THERAPEUTIC DRUG MONITORING (2015)
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
Niels Vande Casteele et al.
GUT (2015)
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
Iris Dotan et al.
INFLAMMATORY BOWEL DISEASES (2014)
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering
Yuan Wang et al.
JOURNAL OF DRUG TARGETING (2014)
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Martin Bortlik et al.
JOURNAL OF CROHNS & COLITIS (2013)
Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies
Christophe Passot et al.
MABS (2013)
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
N. Vande Casteele et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys
Amita Datta-Mannan et al.
MABS (2012)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
Takuo Suzuki et al.
JOURNAL OF IMMUNOLOGY (2010)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Neuropeptides, Mesenteric Fat, and Intestinal Inflammation
Iordanes Karagiannides et al.
NEURAL SIGNALING: OPPORTUNITIES FOR NOVEL DIAGNOSTIC APPROACHES AND THERAPIES (2008)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor α-chain promoter
Ulrich J. H. Sachs et al.
IMMUNOLOGY (2006)
Share Paper
